The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc applies for a Permit for Sale and Distribution of Strangvac in the U.S.
Stockholm, February 16, 2022 – Intervacc AB (publ) announces that the Company’s application for a Permit for Sale and Distribution of Strangvac® in the U.S. has been submitted to the U.S. Department of Agriculture (USDA). Intervacc is seeking approval for...Intervacc has applied for supplementary protection certificates for Strangvac in key European markets
Stockholm, February 1, 2022 – The European patent for Strangvac®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the...New study confirms that Strangvac is likely to be effective against all known strains of Streptococcus equi
Stockholm, January 21, 2022 – In the largest study of its kind, published in the ‘Equine Veterinary Journal’, scientists confirm that the antigens used in the Strangvac vaccine were highly conserved regardless of which strain of Streptococcus equi...Clarification regarding Intervacc’s vaccine Strangvac
Stockholm, December 17, 2021 – Due to the large and volatile trading in the company’s share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales throughout the EU and that sales will start...Nyhetstjänster
